# OnCo record nct05429268 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05429268/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05429268", "NCT05429268" ;
  schema:name "Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma ("@en ;
  schema:alternateName "firmMIND"@en ;
  schema:description "A phase 3 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05429268/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05429268> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-12-23" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/incyte/> .